Other strategies to overcome ICI resistance include combinations of ICIs with inhibitors of proteins that are highly or selectively expressed in SCLC, including PARP, already discussed in previous paragraph, and fucosyl-GM1. This evidence concerns the gene PARP1 and small cell lung carcinoma.